Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ACO1

ACO1

Basics

Aliases:
This biomarker is also known as:
  • EC 4.2.1.3,
  • Iron-responsive element-binding protein 1,
  • IRP1,
  • cytoplasmic aconitate hydratase,
  • IREBP1,
  • ACONS,
  • iron regulatory protein 1,
  • Ferritin repressor protein,
  • iron-responsive element binding protein 1,
  • aconitase 1, soluble,
  • IRE-BP 1,
  • IREB1,
  • iron-responsive element-binding protein 1,
  • citrate hydro-lyase,
  • Iron regulatory protein 1,
  • aconitate hydratase,
  • Citrate hydro-lyase,
  • ferritin repressor protein,
  • Aconitase,
  • IREBP,

View in BioMuta

Description…

aconitase 1, soluble

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: ACO1

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

No additional prostate data available.

Performance Comment

This gene is part of a 114-gene set that comprises a stroma-specific classifier for nearby prostate tumors. Gene expression changes in stroma have been identified that can detect tumor nearby. This classifier predicted the tumor status of patients using tumor-free samples with an average accuracy of 97% (sensitivity = 98% and specificity = 88%) whereas classifiers trained with sets of 100 randomly generated genes had no diagnostic value. These results indicate that the prostate cancer microenvironment exhibits reproducible changes useful for categorizing the presence of tumor in patients when a prostate sample is derived from near the tumor but does not contain any recognizable tumor. (PMID:21459804)

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

No associated resources found.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.